Pharmaceutical Analysis & Statistics in Oceania Countries, May 2013 (p10)

Talk to Nicolas

+1 718 618 4302

Search inside this page

You might be interested in: therapeutics, drug, cancer, more »

271-320 of about 600 reports

Purchase Reports From Reputable Market Research Publishers

Australian Pharmaceutical Industries Ltd in Retailing (Australia)

Australian Pharmaceutical Industries Ltd in Retailing (Australia)

  • $ 153
  • Company report
  • July 2013
  • by Euromonitor International

Australian Pharmaceutical Industries Ltd is planning for rapid expansion in Australia, with the aim of opening at least 400 Priceline stores by 2014. This target amounts to an expansion of up to 50% from ...

  • Industries : Pharmaceutical
  • Countries : Australia
Zuellig Australia Pharmacy Services Pty Ltd in Retailing (Australia)

Zuellig Australia Pharmacy Services Pty Ltd in Retailing (Australia)

  • $ 153
  • Company report
  • July 2013
  • by Euromonitor International

Zuellig Australia Pharmacy Services Pty Ltd is committed to investing in its core business of healthcare in order to help this business grow through organic business expansion. The company is also prepared ...

  • Industries : Pharmacies and Drug Stores, E-commerce
  • Countries : Australia
Vascular Closure Systems, Inc. - Product Pipeline Analysis, 2013 Update

Vascular Closure Systems, Inc. - Product Pipeline Analysis, 2013 Update

  • $ 750
  • Company report
  • July 2013
  • by Global Data

Summary Vascular Closure Systems, Inc (VCS) is a medical device company. The company develops and commercializes vascular access closure technology for the interventional cardiology market. It develops ...

  • Industries : Drug Discovery and Development
  • Countries : United States, Philippines, New Zealand, Australia, Singapore
Vitamin and Supplement Stores in Australia - Industry Market Research Report

Vitamin and Supplement Stores in Australia - Industry Market Research Report

  • $ 890
  • Industry report
  • July 2013
  • by Ibisworld

Healthy growth: Increasing health consciousness and sports participation will enhance industry performance Vitamin and Supplement Stores in Australia This industry consists of physical stores that mainly ...

  • Industries : Vitamin and Supplement
  • Countries : Australia
iNova Pharmaceuticals (Symbol:Australia) SWOT Analysis, Strategy, Revenues and Profits

iNova Pharmaceuticals (Symbol:Australia) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • July 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Pharmaceutical
  • Countries : Australia
Taisho Pharmaceutical Co., Ltd. (Symbol:4535) SWOT Analysis, Strategy, Revenues and Profits

Taisho Pharmaceutical Co., Ltd. (Symbol:4535) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • July 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Pharmaceutical
  • Countries : Japan, Philippines, United States, Asia, Australia, Indonesia
Australian Pharmaceutical Industries Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Australian Pharmaceutical Industries Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Pharmaceutical
  • Countries : Australia
New Zealand Pharmaceuticals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

New Zealand Pharmaceuticals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Pharmaceutical
  • Countries : New Zealand
Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022

Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022

Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022

PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The ...

  • Industries : Pathology
  • Countries : World, Brazil, United States, Spain, Italy, France, Germany, Japan, Australia, Europe, United Kingdom, China
Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022

Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022

Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide (Perera ...

  • Industries : Pathology
  • Countries : Germany, Japan, World, Brazil, Spain, Italy, France, United States, Australia, Europe, United Kingdom, China
Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The ...

  • Industries : Pathology
  • Countries : World, Brazil, United States, Spain, Italy, France, Germany, Japan, Australia, Europe, United Kingdom, China
Apremilast (Psoriasis) - Forecast and Market Analysis to 2022

Apremilast (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Apremilast (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : Italy, France, World, Brazil, Spain, Germany, Japan, United States, United Kingdom, Europe, Australia, China
Alzumab (Psoriasis) - Forecast and Market Analysis to 2022

Alzumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Alzumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide (Perera ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, India, China
Inclusion Body Myositis (IBM) - Pipeline Review, H1 2013

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2013

  • $ 2 000
  • Company report
  • May 2013
  • by Global Markets Direct

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Inclusion Body Myositis (IBM) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic ...

  • Industries : Pathology
  • Countries : New Zealand, World
Pharmaceutical in United States: Hospira, Inc. ? Product Pipeline Review - H2 2011

Pharmaceutical in United States: Hospira, Inc. ? Product Pipeline Review - H2 2011

  • $ 1 500
  • Company report
  • May 2013
  • by Global Markets Direct

- Product Pipeline Review - H2 2011? provides a detailed overview on the Hospira, Inc.?s research and development focus. The report includes data on current developmental pipeline, complete with latest ...

  • Industries : Therapy
  • Countries : United States, India, Australia, World, Japan
Merger & Acquisition in Pharmaceuticals & Healthcare Industry: Telesso Technologies Limited (TEO)

Merger & Acquisition in Pharmaceuticals & Healthcare Industry: Telesso Technologies Limited (TEO)

  • $ 250
  • Company report
  • May 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Pharmaceutical
  • Countries : Australia
NeuroDiscovery Limited (NDL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

NeuroDiscovery Limited (NDL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2013
  • by Global Data

Summary NeuroDiscovery Ltd (NeuroDiscovery) is a neuroscience drug development company, based in Australia. The company provides neuroscience services and drug development. Its products include NSL-101 ...

  • Industries : Drug Discovery and Development
  • Countries : Australia
NeuroDiscovery Limited (NDL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

NeuroDiscovery Limited (NDL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2013
  • by Global Data

Summary NeuroDiscovery Ltd (NeuroDiscovery) is a neuroscience drug development company, based in Australia. The company provides neuroscience services and drug development. Its products include NSL-101 ...

  • Industries : Drug Discovery and Development
  • Countries : Australia
The University of Melbourne - Pharmaceuticals & Healthcare - Deals and Alliances Profile

The University of Melbourne - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2013
  • by Global Data

Summary The University of Melbourne (UM) is an educational service provider. The university provides awareness and management services to the society in the field of research and teaching services. It ...

  • Industries : Pharmaceutical
  • Countries : Australia
Vaccines - Global Markets Package

Vaccines - Global Markets Package

  • $ 24 060
  • Industry report
  • May 2013
  • by Global Research & Data Services

This industry data report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The reports provide essential market ...

  • Industries : Drug and Medication
  • Countries : World, Europe, Asia, South America, Czech Republic, South Korea, Philippines, Africa, Australia, Argentina, United States, United Kingdom, Netherlands, Macedonia, Lithuania, Sri Lanka, Singapore, Kazakhstan, Indonesia, Bangladesh, Azerbaijan, South Africa, Uruguay, Ecuador, Chile, Colombia, Bolivia, Panama, Mexico, Canada, Ukraine, Sweden, Spain, Slovenia, Slovakia (slovak Republic), Russian Federation, Romania, Portugal, Poland, Norway, Moldova, Republic Of, Latvia, Italy, Ireland, Hungary, Greece, France, Germany, Finland, Estonia, Denmark, Bulgaria, Belgium, Austria, Thailand, Pakistan, Nepal, Mongolia, Malaysia, Lebanon, Jordan, Japan, India, China, Georgia, Armenia, Sudan, Senegal, Nigeria, Morocco, Ghana, Ethiopia, Egypt, Kyrgyz Republic (kyrgyzstan), North America, Peru, Oman, Iran
Vaccine Market in Australia

Vaccine Market in Australia

  • $ 652
  • Industry report
  • May 2013
  • by Global Research & Data Services

This industry data report offers a perspective on the actual market situation, trends and future outlook for vaccines in Australia. The report provides essential market data for decision-makers including: ...

  • Industries : Drug and Medication
  • Countries : Australia
Monash University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Monash University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2013
  • by Global Data

Summary Monash University (Monash) is an education center. The University offers a wide range of undergraduate programs and various postgraduate coursework programs. Monash offers its undergraduate and ...

  • Industries : Pathology
  • Countries : Australia
EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022

EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • May 2013
  • by Global Data

EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022 Summary Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an ...

  • Industries : Pathology
  • Countries : World, Australia, Brazil, Spain, United States, United Kingdom, Italy, France, Germany

13 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Management Strategies

United States

Abbott Laboratories

United States

Johnson and Johnson

United States

Medtronic Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.